If you've been watching the news about Ozempic, Wegovy, or Zepbound and wondering whether Medicare would ever help pay for these expensive weight-loss drugs, the answer — at least temporarily — is yes. Starting July 1, 2026, a new federal initiative called the Medicare GLP-1 Bridge Program will provide Part D coverage for three specific GLP-1 medications used for weight reduction and weight management. The program runs for 18 months, through December 2027. A new analysis from KFF estimates that approximately 3.8 million Medicare Part D enrollees met the clinical criteria to be eligible for this program, based on 2023 claims data. That's a meaningful number — but it's also a much smaller group than the 13 million-plus Medicare beneficiaries who simply meet the weight thresholds on paper.
The three drugs covered under the Bridge Program are Wegovy (semaglutide), Zepbound (tirzepatide), and Foundayo — all of which are FDA-approved specifically for chronic weight management, not just blood sugar control. This distinction matters enormously under Medicare rules. Historically, Medicare Part D has been prohibited from covering drugs used solely for weight loss or weight gain under the non-interference provisions of the Medicare Modernization Act of 2003. The Bridge Program represents a deliberate, time-limited policy workaround to get these medications into the hands of Medicare beneficiaries while longer-term coverage solutions are debated in Congress. Think of it as a test run — the federal government is watching participation rates, costs, and health outcomes closely before deciding what comes next.
So who actually qualifies? The clinical criteria are specific, and you need to meet all of them — not just one. First, you must be enrolled in a Medicare Part D plan (either a standalone Prescription Drug Plan or a Medicare Advantage plan that includes Part D drug coverage). Second, you must have a documented BMI of 35 or higher — which falls in the Class II obesity range — OR a BMI of 27 or higher combined with at least one weight-related comorbid condition. Those qualifying comorbidities are expected to include conditions like hypertension, high cholesterol, obstructive sleep apnea, and cardiovascular disease, though you should confirm the exact list with your prescribing physician and Part D plan when the program launches. Third — and this is where many people get tripped up — you cannot have a condition that is already treated by GLP-1 drugs and covered under Part D. The most common example is type 2 diabetes. If you're already taking a GLP-1 like Ozempic or Trulicity for diabetes management, you are not eligible for the Bridge Program because your GLP-1 use is already covered through a different clinical pathway. Fourth, you must not have filled a GLP-1 prescription through your Part D plan at any point in 2026 prior to enrolling in the Bridge Program.
That last criterion is worth pausing on. If you currently take a GLP-1 drug for any reason covered under Part D — diabetes, cardiovascular risk reduction, or otherwise — you are excluded from the Bridge Program. This is why the eligible population shrinks so dramatically from 13 million beneficiaries who meet the BMI thresholds down to 9.7 million who meet the clinical criteria, and then further down to 3.8 million who meet all eligibility requirements including the Part D enrollment and prior-use exclusions. The program is specifically designed to reach Medicare beneficiaries who have obesity or overweight with complications but are not currently receiving GLP-1 therapy through Medicare.
What will this actually cost you out of pocket? The program is structured with a $50 monthly copay per beneficiary. The federal government's net monthly cost per participating beneficiary is estimated at $245 — meaning the total monthly drug cost is approximately $295, with Medicare absorbing $245 and you paying $50. To put that in perspective, the retail list price for Wegovy runs approximately $1,350 per month without insurance, so even the $50 copay represents a dramatic reduction in what you'd pay at the pharmacy counter. Whether your specific Part D plan applies any additional cost-sharing on top of the $50 copay is something you'll want to verify directly with your plan, since Medicare Advantage plans with Part D coverage can structure their formularies differently within program guidelines.
The total federal cost of the Bridge Program will vary significantly depending on how many eligible beneficiaries actually participate. According to the KFF analysis, if just 10% to 25% of the 3.8 million eligible beneficiaries participate starting in July 2026 and fill a prescription every month for the full 18-month duration, the cost to Medicare would range from $1.3 billion to $3.3 billion. If participation climbs to 50% to 75% of eligible enrollees, the cost balloons to between $6.7 billion and $10 billion. These projections underscore why the program is temporary — policymakers need real-world data on uptake and cost before committing to permanent coverage of GLP-1 drugs for weight loss across the entire Medicare population.
Data Snapshot: According to CMS.gov data, approximately 51.4 million Medicare beneficiaries were enrolled in Part D drug coverage as of 2024, including both standalone PDPs and Medicare Advantage plans with drug coverage. Of those, the KFF analysis estimates 9.7 million met the clinical BMI and comorbidity criteria for the Bridge Program — roughly 19% of all Part D enrollees. The 3.8 million who meet all eligibility criteria (including the exclusion of current GLP-1 users and the Part D enrollment requirement) represent about 7.4% of total Part D enrollment. CMS.gov also reports that in 2025, Medicare Advantage plans with Part D coverage were available in virtually every U.S. county, with an average of 43 MA-PD plans per county — meaning most beneficiaries have multiple plan options through which they could access the Bridge Program.
If you think you might qualify, the most important first step is talking to your primary care physician before July 1, 2026. Your doctor will need to document your BMI and any qualifying comorbidities in your medical record, and they'll need to write a prescription for one of the three covered drugs. Not every physician is familiar with the Bridge Program's specific eligibility criteria yet, so it may help to bring printed information from Medicare.gov or CMS.gov to your appointment. Ask your doctor specifically whether your BMI is documented in your chart, whether you have any qualifying comorbid conditions, and whether there's any clinical reason you shouldn't use a GLP-1 medication. These drugs do carry side effects — nausea, vomiting, and gastrointestinal discomfort are common, particularly when starting — and they're not appropriate for everyone.
Once you have a prescription, contact your Part D plan directly to confirm how the Bridge Program will be administered through their formulary. Medicare Advantage plans with Part D coverage may have prior authorization requirements, step therapy protocols, or other utilization management tools in place. Prior authorization means your plan may require documentation from your doctor before they'll approve coverage — this is common for high-cost specialty drugs and is likely to apply here. Step therapy means the plan might require you to try a less expensive medication first, though Bridge Program regulations may limit how aggressively plans can apply step therapy to these specific drugs. Call the member services number on the back of your insurance card and ask specifically: Does my plan cover the Medicare GLP-1 Bridge Program? What documentation do I need to submit? Is prior authorization required, and how long does approval typically take?
It's also worth understanding what happens after December 2027 when the Bridge Program ends. This is a temporary program, and there is currently no permanent Medicare coverage mandate for GLP-1 drugs used solely for weight loss. Congress has debated the Treat and Reduce Obesity Act for years without passing it. If you start one of these medications through the Bridge Program and it's working well for you, you'll need a plan for what comes next. Some Medicare Advantage plans may choose to continue covering these drugs after the Bridge Program ends — that's a plan-by-plan decision. Standalone Part D plans are less likely to do so without a federal mandate. The out-of-pocket cost of Wegovy or Zepbound without coverage can exceed $1,000 per month, so this is not a trivial consideration. Talk to your doctor now about what a realistic long-term treatment plan looks like, including whether lifestyle modifications, other medications, or other interventions might be part of your strategy.
For beneficiaries who don't qualify for the Bridge Program — perhaps because you have type 2 diabetes and already receive GLP-1 coverage through Part D, or because your BMI falls below the thresholds — it's worth knowing that GLP-1 drugs prescribed for diabetes (like Ozempic and Mounjaro) are already covered under Part D when used for blood sugar management. If your doctor believes a GLP-1 is clinically appropriate for your diabetes care, that coverage pathway already exists and is not affected by the Bridge Program. The Bridge Program is specifically and exclusively for the weight-loss indication in people who are not already using these drugs for another covered condition.
Finally, be cautious about unsolicited calls or mailers claiming to help you enroll in the Medicare GLP-1 Bridge Program. As with any new Medicare benefit, scammers move quickly to exploit confusion around new programs. Medicare will not call you unsolicited to enroll you in the Bridge Program. Your Part D plan will communicate changes through official plan documents and their member services line. If you receive a call from someone claiming to be from Medicare and asking for your Medicare number or personal information in connection with GLP-1 coverage, hang up and call 1-800-MEDICARE (1-800-633-4227) directly to report it and get accurate information.